Bröcker E B, Suter L, Czarnetzki B M, Macher E
Cancer Immunol Immunother. 1986;23(2):155-7. doi: 10.1007/BF00199823.
Previously, we have provided evidence for a positive correlation between HLA-DR expression in primary melanoma and early metastasis. In the present study we investigated whether this relationship was modified by adjuvant BCG immunotherapy. The study comprised 107 patients with a stage I high-risk melanoma; 44 patients had been treated with BCG, whereas the remaining patients had not received any adjuvant therapy. There was no difference in disease-free survival between BCG-treated and untreated patients. Disease-free survival was significantly shorter in patients with high expression of HLA-DR antigens in the primary tumor. Subgrouping BCG-treated and control patients according to HLA-DR phenotype of the melanoma revealed a prolongation of disease-free survival in the subgroup of BCG-treated patients with no or low expression of HLA-DR antigens in the primary melanoma. BCG therapy apparently did not influence prognosis of patients with high expression of HLA-DR antigens in the tumor.
此前，我们已提供证据表明原发性黑色素瘤中HLA - DR表达与早期转移之间存在正相关。在本研究中，我们调查了这种关系是否会因辅助性卡介苗免疫疗法而改变。该研究纳入了107例I期高危黑色素瘤患者；44例患者接受了卡介苗治疗，其余患者未接受任何辅助治疗。接受卡介苗治疗和未接受治疗的患者之间无病生存期没有差异。原发性肿瘤中HLA - DR抗原高表达的患者无病生存期明显较短。根据黑色素瘤的HLA - DR表型对接受卡介苗治疗的患者和对照患者进行亚组分析发现，原发性黑色素瘤中无或低表达HLA - DR抗原的接受卡介苗治疗的患者亚组无病生存期延长。卡介苗治疗显然对肿瘤中HLA - DR抗原高表达的患者预后没有影响。
